Funder: National Institutes of Health (NIH)
Due Dates: March 4, 2024 | October 21, 2024 | June 23, 2025 | February 23, 2026 | October 20, 2026
Funding Amounts: Up to $350,000 direct costs per year for up to 3 years (R61 phase) plus up to 3 years (R33 phase), total up to 5 years.
Summary: Supports early phase clinical trials of natural products to test target engagement and optimize dosing, with a phased R61/R33 mechanism requiring clinical trials.
Key Information: Requires a Plan for Enhancing Diverse Perspectives (PEDP); only supports trials of natural products with strong scientific premise; no efficacy or cancer prevention/treatment trials; transition to R33 contingent on R61 milestones.